Professional
Added to YB: 2024-07-24
Pitch date: 2024-06-30
RGEN [bullish]
Repligen Corporation
+24.97%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Market Cap
$8.6B
Pitch Price
$125.94
Price Target
N/A
Dividend
N/A
EV/EBITDA
51.33
P/E
6.0K
EV/Sales
12.03
Sector
Life Sciences Tools and Services
Category
turnaround
Show full summary:
Parnassus Mid Cap Fund Portfolio Holding: Repligen Corporation
RGEN: Bioprocessing leader; Q1 revenue soft, stock down on CEO transition. Outgoing CEO stays as exec chair. Well-positioned for cyclical upturn. Temporary setback in strong long-term growth story.
Read full article (1 min)